EMAIL THIS PAGE TO A FRIEND

Expert review of gastroenterology & hepatology

Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.


PMID 22928902

Abstract

To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D193
DL-α-Difluoromethylornithine hydrochloride hydrate, solid, ≥97% (NMR)
C6H12F2N2O2 · xHCl · yH2O